American personal genomics company / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about 23andMe?
Summarize this article for a 10 years old
23andMe Holding Co. is a publicly held personal genomics and biotechnology company based in South San Francisco, California. It is best known for providing a direct-to-consumer genetic testing service in which customers provide a saliva sample that is laboratory analysed, using single nucleotide polymorphism genotyping, to generate reports relating to the customer's ancestry and genetic predispositions to health-related topics. The company's name is derived from the 23 pairs of chromosomes in a diploid human cell.
|Founded||April 2006; 17 years ago (2006-04)|
|Anne Wojcicki (CEO)|
Esther Dyson (board member)
|Products||Direct-to-consumer personal genome testing |
|Services||Genetic testing, genealogical DNA testing, medical research|
|Revenue||US$299 million (2023)|
|US$−324 million (2023)|
|US$−312 million (2023)|
|Total assets||US$943 million (2023)|
|Total equity||US$714 million (2023)|
Number of employees
|Footnotes / references|
Financials as of March 31, 2023[update]
The company had a previously fraught relationship with the United States Food and Drug Administration (FDA) due to its genetic health tests; as of October 2015, DNA tests ordered in the US include a revised health component, per FDA approval. 23andMe has been selling a product with both ancestry and health-related components in Canada since October 2014, and in the UK since December 2014.
In 2007, 23andMe became the first company to begin offering autosomal DNA testing for ancestry, which all other major companies now use. Its saliva-based direct-to-consumer genetic testing business was named "Invention of the Year" by Time in 2008.